Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 12:4:75.
doi: 10.3310/nihropenres.13784.1. eCollection 2024.

The Midlands Liver Research Alliance - A partnership to optimise obesity-related liver disease research: targeting areas of high incidence and underserved communities

James King  1   2 , Guruprasad Aithal  1   2 , Louisa Herring  3   4 , Scott Willis  3   4 , Dimitris Papamargaritis  3   5 , Kerry Hulley  6 , Melanie Davies  3   6
Affiliations

The Midlands Liver Research Alliance - A partnership to optimise obesity-related liver disease research: targeting areas of high incidence and underserved communities

James King et al. NIHR Open Res. .

Abstract

Background: The prevalence of liver disease is rising in the United Kingdom (UK), with obesity underpinning surging metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD is associated with an increased cardiometabolic risk, particularly when co-existing with type 2 diabetes. Progression to metabolic dysfunction-associated steatohepatitis (MASH) with hepatic fibrosis represents a clinical milestone strongly linked to serious liver disease and mortality.Therefore, clinically meaningful and sustained weight loss (≥10%) is a primary therapeutic target for patients with MASLD. Unfortunately, this is difficult for most people who adopt traditional lifestyle approaches. However, new obesity pharmacotherapies hold promise in MASLD, given their ability to produce dramatic weight loss (10-25%) and improve cardiometabolic health. Questions remain about the ability of these agents to improve liver fibrosis and patient-reported outcomes/quality of life in patients with advanced liver disease.

Methods: Led from the Midlands (UK) but with national representation, we developed a network of stakeholders (clinicians, academics, third-sector, industry, and PPIE representatives) with an interest in obesity-related liver diseases. This network was called the Midlands Liver Research Alliance (MLRA), which sought to 1) establish a PPIE stakeholder network, 2) identify research priorities, and 3) map the network infrastructure and expertise. Health inequalities within liver disease are a core priority within the MLRA.

Results: The MLRA developed a large PPIE stakeholder network in collaboration with other local liver partnerships. These networks facilitated the identification of key research priorities that led to three NIHR funding applications. Priorities centered around: 1) the importance of patient-centered outcomes in obesity-related liver disease research; 2) the potential of glucagon-like peptide 1 (GLP-1)-based obesity pharmacotherapy in alcohol use disorder; and 3) early identification and management of liver disease in primary care/community.

Conclusions: The MLRA has created a multidisciplinary hub of research expertise in obesity-related liver disease. This foundation provides a springboard for research activities in this area.

Keywords: Liver; education; exercise; metabolic dysfunction-associated steatotic liver disease (MASLD); nutrition; patient-reported outcomes; physical activity.

Plain language summary

Liver disease is a major cause of death worldwide and is becoming more common each year. This is mostly due to fat in the wrong place in the liver, which can cause liver cirrhosis (scarring). The causes include obesity, type 2 diabetes, and excessive alcohol consumption. These problems are often linked to lifestyle choices such as not exercising enough and eating unhealthy foods. The Midlands Liver Research Alliance (MLRA) is a partnership made up of researchers, health care professionals, people with liver disease, and charities, funded by the NIHR to identify gaps in liver disease care and research in areas most in need. Leicester, Nottingham, and Birmingham’s Biomedical Research Centers are leading experts in liver and obesity research and have led the MLRA partnership. The MLRA established an inclusivity and engagement network, identified research experts and centers, and set important liver research priorities. The three liver research priority areas the MLRA has and will continue to focus on are: Experimental medicine - research focusing on the impact of obesity medications and lifestyle activities such as exercise on this type of liver disease. Addressing health inequalities in liver disease - within our diverse region, working with expert centers and charities to reduce inequalities relating to ethnicity, socioeconomic position, and coastal communities within liver disease. Liver disease management in primary care: work with GP practices to provide liver disease education for healthcare professionals to help early identification and management. Provide education and support for people at risk of liver disease. The MLRA uses this extensive knowledge gathered from MLRA priority setting activities and collaborative activities with other liver partnerships to inform future research and continue collaborations in this important area.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. The Midlands Liver Research Alliance partners and local NIHR liver research activity.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Younossi ZM, Golabi P, Paik JM, et al. : The global epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. 10.1097/HEP.0000000000000004 - DOI - PMC - PubMed
    1. Hagström H, Shang Y, Hegmar H, et al. : Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9(10):944–56. 10.1016/S2468-1253(24)00193-6 - DOI - PubMed
    1. Rinella ME, Sanyal AJ: Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13(4):196–205. 10.1038/nrgastro.2016.3 - DOI - PubMed
    1. Melson E, Ashraf U, Papamargaritis D, et al. : What is the pipeline for future medications for obesity? Int J Obes (Lond). Online ahead of print,2024. 10.1038/s41366-024-01473-y - DOI - PMC - PubMed
    1. Wilding JPH, Batterham RL, Calanna S, et al. : Once-Weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. 10.1056/NEJMoa2032183 - DOI - PubMed

LinkOut - more resources